2025 · 2nd Quarter (Apr 1 - June 30)

FOUNDATION MEDICINE, INC.

Filed by FOUNDATION MEDICINE, INC..

Open official filing

Source-reported fields

Filing overview

Type: 2nd Quarter - Report
Posted: Jul 18, 2025
Income: Not reported
Expenses: $80,000.00
Registrant: FOUNDATION MEDICINE, INC.
Client: FOUNDATION MEDICINE, INC.
Filing UUID: 2cce2f34-4558-435b-a433-7a0293bf25f4
Termination date: Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

- Coverage and reimbursement of biomarker testing, including the Cancer Patient Equity Act of 2021(H.R.5377) - Diagnostic regulatory reforms, including the Verifying Accurate Leading-edge IVCT Development Act of 2023 (H.R.2369) and the pilot program for Oncology Drug Products Used with Certain In Vitro Diagnostic Tests - Price transparency for clinical laboratory diagnostic tests, including the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 (H.R.3561) - Import of biological specimens for testing in a clinical laboratory

Literal federal measure citations: H.R.5377, H.R.2369, H.R.3561

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.